A gut microbe’s protective coat is 3x less common in Crohn’s patients

A common gut bacterium called Mediterraneibacter gnavus has been associated with Crohn’s disease for years, but the molecular reason why remained unclear. A study published in Nature Communications now points to a specific surface structure: a sugar-based coating called capsular polysaccharide, or CPS. When M. gnavus carries this coating, it colonizes the intestine effectively and produces a weaker inflammatory signal. Without it, the bacterium cannot compete for space in the gut and triggers a more aggressive immune response. That pattern shows up in both mouse experiments and in genomic data drawn from human patient samples.

Capsular Polysaccharide Surface Coat Governs M. gnavus Gut Colonization

The research was led by Nozomu Obana at the Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan, with Shinji Fukuda as the corresponding author. Before this study, M. gnavus was difficult to genetically manipulate, which made it hard to test what the bacterium actually does in the gut.

The team identified two enzymes of the sortase family as key players. SrtB3 anchors superantigen proteins called IbpA and IbpB to the bacterial cell wall. SrtB4 is responsible for attaching the CPS coating to the cell surface.

When the researchers disabled the gene for SrtB4, producing a mutant strain with no CPS, the results were unambiguous. In competitive colonization experiments using germ-free mice, the CPS-deficient mutant was rapidly outcompeted by wild-type M. gnavus and became essentially undetectable within two weeks. The surface coating was not incidental to gut survival; it was essential.

Crohn’s Disease Patients Carry a Different Form of the Bacterium

The genomic data sharpened the picture. The team sequenced 40 M. gnavus isolates, 26 collected from healthy individuals and 14 from patients with Crohn’s disease, a chronic inflammatory condition that causes pain and disruption along stretches of the digestive tract. The gene cluster required for CPS production was present in 69% of the healthy-individual isolates. In the Crohn’s disease isolates, that figure dropped to just 21%.

That works out to roughly 3.3 times more prevalent in healthy individuals than in Crohn’s disease patients, a gap large enough to suggest the strains are not interchangeable.

The functional experiments in mice supported the same direction. When germ-free mice were colonized with the CPS-deficient strain and macrophages were stimulated in the lab, those immune cells produced elevated levels of TNF-alpha, a central pro-inflammatory molecule. In a mouse colitis model, animals colonized with the CPS-lacking bacteria showed more severe weight loss and a higher disease activity index than animals colonized with normal M. gnavus.

A New Genetic Toolkit Unlocked the Biology

The mechanistic findings depended entirely on the ability to create precise genetic changes in M. gnavus, something that had not been possible before. Part of the paper’s contribution is the toolkit itself: shuttle vectors for moving DNA into the bacterium, inducible promoters, fluorescent reporter genes for tracking bacteria in live tissue, Clostron-based gene disruption, and CRISPR/Cas9 deletion systems.

These tools allowed the team to knock out srtB4 specifically and confirm that the loss of CPS, rather than some off-target change, was responsible for the colonization failure and the elevated inflammatory response. Without that precision, the genomic correlation between CPS-negative strains and Crohn’s disease would remain intriguing but uninterpretable.

The toolkit also has value beyond these findings. Other researchers working on M. gnavus biology can now use the same methods to test different genetic targets in the same bacterium.

Small Sample Sizes Leave Room for Doubt

The study’s conclusions come with limits worth stating clearly. The competitive colonization experiments used groups of just 4 to 7 mice, which limits statistical confidence. The macrophage stimulation data came from three independent in vitro experiments. Neither is a clinical trial.

The genomic dataset is also small. Forty isolates from 26 healthy individuals and 14 Crohn’s disease patients is too few to adjust for potential confounders such as antibiotic use, diet, or geographic region. The 69% vs. 21% gap is large, but small datasets can produce striking correlations that shrink under larger scrutiny.

Critically, the study shows an association, not a causal direction. It is possible that the gut environment characteristic of inflammatory bowel disease selects against CPS-producing strains, rather than CPS-negative strains helping to drive disease. That question is not answered by the current data.

A Molecular Handle for Future Gut Microbiome Research

The genetic toolkit opens several concrete directions. Larger surveys of M. gnavus isolates from IBD patients could determine whether the CPS distribution pattern holds at a meaningful scale. Longitudinal studies could track whether patients who develop Crohn’s disease experience a shift in M. gnavus strain type before or around the time of diagnosis.

CPS-competent strains could in principle be evaluated as probiotic candidates, though the researchers have not proposed that path specifically, and safety and efficacy in humans would need to be established from scratch. What the study does provide is a specific, testable molecular target: the CPS surface coat encoded by the srtB4 gene cluster.

M. gnavus is a common gut bacterium that had long been linked to disease mainly through epidemiological patterns. The association still needs to be confirmed in larger human studies, but researchers now have a mechanism to investigate and, for the first time, a set of genetic tools to investigate it with.

References

1. Nozomu Obana, Gaku Nakato, Nobuhiko Nomura, Shinji Fukuda (2026). A genetic toolkit for the human gut bacterium Mediterraneibacter gnavus identifies capsular polysaccharides as a competitive colonization factor. Nature Communications. https://doi.org/10.1038/s41467-026-69022-x